Training · GLP-1s
A large body of research with a specific hole in the middle of it
There is a lot of research on these drugs and muscle. There are body scan side-studies from the major drug studies, and four reviews in 2026 alone. There are studies that assigned people to drugs built to protect muscle during weight loss. And there is one landmark study that added exercise to a GLP-1 and followed people for two years. Anyone who says the field is empty has not looked.
The hole is narrower and more specific than that. No published study has assigned people to strength training that gets steadily heavier while on semaglutide, tirzepatide or retatrutide, and measured what happened. The advice everybody gives, lift and eat protein while you are on it, is the one combination nobody has tested yet.
What the research contains
tested in people
Adding exercise to the drug changed body fat, but not the weight on the scale
Who was studied
195 adults with obesity and no diabetes. After an 8 week low-calorie diet, they were split by chance into four groups for one year: exercise plus a dummy shot, liraglutide 3.0 mg alone, both together, or neither.
Compared with liraglutide alone, adding exercise cut body fat by a further 1.9 percentage points. That roughly doubled the fat loss of either one by itself. Only the combination improved long-term blood sugar (HbA1c), how well the body uses insulin, and heart and lung fitness. This is the study the whole field leans on.
Study in peopleHealthy weight loss maintenance with exercise, liraglutide, or both combined (2021)What this does not show
That the combination beat the drug for weight. It did not. The difference was 2.7 kg, and it could easily have been zero. More important for anyone reading this as a training guide: the exercise was supervised cycling and circuit work, not steadily heavier weight training. No protein target was set during the year. The thing usually recommended is not the thing this study tested.
tested in people
A drug added 6% lean mass and did not improve anything people could do
Who was studied
180 adults aged 70 and over, living at home, with age-related muscle loss (judged by walking speed and muscle size). They were at 38 sites in 13 countries. They got bimagrumab or a dummy shot monthly for 6 months, plus a good diet and home exercise.
Bimagrumab raised lean mass by 7%, against 1% on the dummy shot, a 6 point difference. But it did not help with anything people could do. A standard test of balance, walking and standing, how far people walked in six minutes, and walking speed all came out the same in both groups. Both groups got better at these, and the authors credit the diet and exercise both groups got.
Study in peopleBimagrumab vs optimized standard of care for treatment of sarcopenia in community-dwelling older adults: a randomized clinical trial (2020)What this does not show
That muscle does not matter. It shows that lean mass on a scan and being able to do things are different goals, and adding the first does not give you the second. This is the clearest evidence there is that anyone chasing a body scan number, with a drug or any other way, has picked the wrong goal.
tested in people
The one study of tirzepatide plus training has been pulled
Who was studied
61 men with obesity and early blood sugar problems (prediabetes), split by chance into six groups for 6 weeks: a dummy shot, tirzepatide at 2.5 or 5 mg, and weight training plus cardio with or without each dose
It reported that training alone beat tirzepatide on fitness, strength and insulin, and that adding the drug to training did no better than training alone. It was pulled in 2025, and PubMed now marks the original as pulled.
Study in peopleTirzepatide and exercise training in obesity (RETRACTED) (2024)What this does not show
Anything, and that is why it is here. Its numbers still get passed around, and its conclusion is exactly the kind people repeat, so anyone looking into tirzepatide and training will run into it. It was also six weeks, in 61 men, split six ways. That is around ten people per group, even before anyone questioned the data.
watched in people
Four reviews published in 2026 reach four different conclusions
Who was studied
Four separate reviews of muscle and fat loss on GLP-1 type weight-loss drugs, published within months of each other. They pooled overlapping but differently chosen sets of studies.
One looked only at studies with at least 10% weight loss. It found 33.3% of the weight lost on the drugs was lean mass (muscle, bone, water and organs), against 22.3% on diet alone. A second was four times larger, without that limit, and found no clear difference between the drugs and diet and exercise at all. A third concluded lean mass was mostly kept and the losses were small. A fourth found the studies so mixed and so loose that it rated its confidence low to very low and refused to draw a conclusion.
Review of studiesBody composition remodelling during GLP-1-based therapy: a systematic review and meta-analysis using a hierarchical physiological framework (2026)What this does not show
That any of them is wrong. They differ because they picked different studies, compared against different things and used different weight-loss cutoffs. That is what happens when an urgent question runs ahead of the evidence. The fourth is probably the most honest. It says lean mass loss should not be read as disease-level muscle loss. It also says the evidence is not good enough to rule out muscle loss that matters in people who are frail or at risk.
Why four reviews of the same question disagree
It is worth understanding, because it will keep happening. It also explains why two people can both cite a 2026 review that pooled studies and say opposite things.
The choices that drive the disagreement are all made before any data is pooled. Whether to include only studies where people lost a lot of weight changes the comparison completely. A lifestyle group that lost three kilos is not a fair test against a drug group that lost twenty. Whether the comparison is a dummy drug, diet, or diet plus training changes the answer. Whether lean mass is reported in kilograms or as a share of weight lost changes which way the result points. None of these is cheating. They are judgement calls. They are the reason the most careful of the four rated its own certainty as low to very low and declined to conclude anything.
What none of them disagree about is the direction training pushes. Where a strength training group existed, it had the lowest share of weight lost as lean tissue in the analysis. That group was almost always measured without anybody taking a GLP-1. So applying it to a person on one is a stretch beyond the data, and we are telling you that rather than dressing it up as a finding.
The lesson from the drug that worked and did nothing
Bimagrumab is the most useful result on this page. In 180 older adults with age-related muscle loss (sarcopenia), it did exactly what it was built to do. It added six percentage points of lean body mass over a dummy drug, a gap far too big to be chance. Then every measure of physical function came back with no difference. Walking speed, six minute walk distance and the physical performance test all failed to beat the dummy drug.
Both groups did improve, and the authors credit the diet and the light home exercise that everybody in the study got. Which is the uncomfortable summary: in that study the food and the movement did the work, and the drug that reliably built tissue did not add to it.
Carry that across to the question people are actually asking about GLP-1s. If your goal is a better number on a body scan, that can be done, and it has been done with a drug. If your goal is to be able to get off the floor at eighty, the scan is only a stand-in for that. This study is a warning about how loose a stand-in it can be.
When the answer arrives
More than a dozen studies are registered that combine strength training, protein targets or both with these drugs, and none has posted results. The best designed of them splits people on semaglutide or tirzepatide into four groups: strength training, a higher protein target, both, or neither. Its main measure is thigh muscle on MRI, and it is run by a university group, not a drug maker. It is due to finish in August 2029. Until then, anyone stating confidently what training does on these drugs is reasoning from nearby evidence. That is reasonable, and it is not the same as knowing.
If the reason you are lifting on a GLP-1 is peri or post menopause, start at the peri FAQ. This page stays the training evidence.
Questions people ask about this
- Is there research on GLP-1 drugs and training?
- A great deal, and it is growing fast. There are body scan side-studies from the major drug studies, and four reviews published in 2026 alone. There are studies that assigned people to drugs designed to protect muscle during weight loss. And there is a landmark study that combined exercise with liraglutide. What does not exist is a published study that assigned people to strength training, getting steadily heavier, while on semaglutide, tirzepatide or retatrutide. Those two statements are both true, and they are usually confused for each other.
- Does tirzepatide have exercise data?
- One study that assigned people to it combined tirzepatide with strength and cardio training. It was withdrawn (retracted) in 2025, and PubMed flags the original as a retracted paper, so its results cannot be used. Its numbers still go around. Tirzepatide does have body scan data from SURMOUNT-1 (a DXA scan) and SURPASS-3 (MRI). Neither of those included a training program.
- What about retatrutide?
- A side-study of an early retatrutide study, in people with type 2 diabetes, measured fat and lean mass by DXA scan in the people who had scans before and after. There is no exercise part in it. No study that assigned people to train on retatrutide exists at all.
- So should I lift while taking one of these?
- The reasoning for it is strong, and the direct study evidence is missing. It is worth knowing which is which. Studies that assigned people to strength training show it builds and protects muscle in people who are not on these drugs, including when they eat less than they burn. Nobody has yet published a study putting that together with a GLP-1. The first one designed to answer it properly reports in 2029.
- If a drug can add lean mass, is that not simpler than training?
- One of the most useful results here says no. Bimagrumab added 6 percentage points of lean body mass over a dummy drug in older adults with age-related muscle loss (sarcopenia). It improved not one measure of physical function. Walking speed, the six minute walk and the physical performance test all showed no difference. Adding tissue to a scan and improving what a person can do turned out to be different things.